Press release content from NewMediaWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from NewMediaWire
Press release content from NewMediaWire. The AP news staff was not involved in its creation.

AngioSoma Developing Male Enhancement Supplement

January 6, 2020 GMT
AngioSoma, Inc.
AngioSoma, Inc.

Houston, TX - ( NewMediaWire ) - January 6, 2020 - AngioSoma Inc. ( OTC: SOAN) (“AngioSoma” or the “Company”) today announced development of Full Salute™, a male ED (erectile dysfunction) product that contains E. brevicornum extract, an all-natural phosphorodiesterase-5 inhibitor (biosimilar to Cialis and Viagra).

The male ED market is large and diverse and will require ingenuity and skill in marketing to the at least 50 million men that complain of male impotency. With the proper advertising we could probably achieve 2-3 million customers annually.

“The successful development and marketing of a product biosimilar to Cialis and Viagra can provide a significant addition to our line of products that provide synergistic or complementary effects to an organ system of the body,” said Alex Blankenship, CEO of AngioSoma. “This new product will further complement the roll-out of our Muscles4U workout enhancement products during the following year.”


AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™.  SomaCeuticals’s experienced team of industry first movers and enterprising visionaries has acquired a diversified supply of supplements, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com.  Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook.


This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.


AngioSoma, Inc.

Alex Blankenship


(832) 781- 8521